The stock of Sangamo Therapeutics Inc (NASDAQ:SGMO) last traded at $0.70, down -27.55% from the previous session.
SGMO stock price is now -7.20% away from the 50-day moving average and -11.70% away from the 200-day moving average. The market capitalization of the company currently stands at $125.77M.
With the price target reduced from $6 to $2, RBC Capital Mkts Downgraded its rating from Outperform to Sector Perform for Sangamo Therapeutics Inc (NASDAQ: SGMO). On April 28, 2023, BofA Securities Downgraded its previous ‘Neutral’ rating to ‘Underperform’ on the stock reducing its target price from $5 to quote $1.50, while ‘Wedbush’ rates the stock as ‘Outperform’
In other news, BIOGEN INC., 10% Owner sold 6,000,000 shares of the company’s stock on Sep 26 ’23. The stock was sold for $3,000,000 at an average price of $0.50. Upon completion of the transaction, the 10% Owner now directly owns 17,652,466 shares in the company, valued at $12.36 million. A total of 11.57% of the company’s stock is owned by insiders.
During the past 12 months, Sangamo Therapeutics Inc has had a low of $0.29 and a high of $1.94. As of last week, the company has a debt-to-equity ratio of 0.46, a current ratio of 1.98, and a quick ratio of 1.98. The fifty day moving average price for SGMO is $0.7604 and a two-hundred day moving average price translates $0.7935 for the stock.
The latest earnings results from Sangamo Therapeutics Inc (NASDAQ: SGMO) was released for Dec, 2023. According to the Biotechnology Company, earnings per share came in at -$0.34, missing analysts’ expectations of -$0.26 by -0.08. This compares to -$0.32 EPS in the same period last year. The net profit margin was -146.30% and return on equity was -136.48% for SGMO. The company reported revenue of $2.04 million for the quarter, compared to $27.23 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -92.5 percent. For the current quarter, analysts expect SGMO to generate $6.65M in revenue.
